How disease advocacy organizations participate in clinical research: A survey of genetic organizations

Genetics in Medicine

Volumn 14, Issue 2, 2012, Pages 223-228

  Landy, David C ^a   Brinich, Margaret A ^b   Colten, Mary Ellen ^c   Horn, Elizabeth J ^d   Terry, Sharon F ^d   Sharp, Richard R ^b,e,f  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF MASSACHUSETTS BOSTON   (United States)

^d GENETIC ALLIANCE   (United States)

^e CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^f CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

clinical research; ethics; genetic research; genetics; voluntary health agencies

Indexed keywords

ARTICLE; CLINICAL RESEARCH; DATA ANALYSIS; DISEASE REGISTRY; FINANCIAL MANAGEMENT; GENETIC ORGANIZATION; HEALTH SURVEY; HUMAN; INFORMATION PROCESSING; LEADERSHIP; PARTICIPATORY RESEARCH; PATIENT ADVOCACY; STUDY DESIGN;

BIOMEDICAL RESEARCH; DATA COLLECTION; FINANCIAL SUPPORT; GENETIC DISEASES, INBORN; GENETICS, MEDICAL; HUMANS; PATIENT ADVOCACY; PATIENT EDUCATION AS TOPIC; PATIENT SELECTION; RESEARCH DESIGN; SELF-HELP GROUPS;

EID: 84856743448     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.0b013e3182310ba0     Document Type: Article

References (32)

1. Li B, Leal SM. Discovery of rare variants via sequencing: implications for the design of complex trait association studies. PLoS Genet 2009;5:e1000481.
2. Katsios C, Ziogas DE, Liakakos T, Zoras O, Roukos DH. Translating Cancer Genomes Sequencing Revolution into Surgical Oncology Practice. J Surg Res, in press.
3. McLaughlin VV, Suissa S. Prognosis of pulmonary arterial hypertension: the power of clinical registries of rare diseases. Circulation 2010;122:106-108.
4. Groft SC, de la Paz MP. Rare diseases-avoiding misperceptions and establishing realities: the need for reliable epidemiological data. Adv Exp Med Biol 2010;686:3-14.
5. Griggs RC, Batshaw M, Dunkle M, et al. Clinical research for rare disease: opportunities, challenges, and solutions. Mol Genet Metab 2009;96: 20-26.
6. Kinder B, McCormack FX. Clinical trials for rare lung diseases: lessons from lymphangioleiomyomatosis. Lymphat Res Biol 2010;8:71-79.
7. Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 2011;29: 551-565.
8. Brewer GJ. Drug development for orphan diseases in the context of personalized medicine. Transl Res 2009;154:314-322.
9. Schilsky RL. Accrual to cancer clinical trials in the era of molecular medicine. Sci Transl Med 2011;3:75cm9.
10. Terry SF, Terry PF. Power to the people: participant ownership of clinical trial data. Sci Transl Med 2011;3:69cm3.
11. Braun MM, Farag-El-Massah S, Xu K, Coté TR. Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years. Nat Rev Drug Discov 2010;9:519-522.
12. Joppi R, Bertele V, Garattini S. Orphan drug development is not taking off. Br J Clin Pharmacol 2009;67:494-502.
13. Faucett WA, Hart S, Pagon RA, Neall LF, Spinella G. A model program to increase translation of rare disease genetic tests: collaboration, education, and test translation program. Genet Med 2008;10:343-348. (Pubitemid 351770404)
14. Connor E, Cure P. "Creating hope" and other incentives for drug development for children. Sci Transl Med 2011;3:66cm1.
15. Terry SF, Terry PF, Rauen KA, Uitto J, Bercovitch LG. Advocacy groups as research organizations: the PXE International example. Nat Rev Genet 2007;8:157-164. (Pubitemid 46122844)
16. Ledbetter DH. Gene patenting and licensing: the role of academic researchers and advocacy groups. Genet Med 2008;10:314-319. (Pubitemid 351770399)
17. Terry SF, Boyd CD. Researching the biology of PXE: partnering in the process. Am J Med Genet 2001;106:177-184. (Pubitemid 32983384)
18. Michael J Fox Foundation, 2010. Epitomics, Inc. announces worldwide availability of LRRK2 antibodies developed in partnership with the Michael J Fox Foundation [press release]. http://www.michaeljfox.org/newsEvents- parkinsonsInTheNews-article.cfm?ID-668#.
19. Dunkle M, Pines W, Saltonstall PL. Advocacy groups and their role in rare diseases research. Adv Exp Med Biol 2010;686:515-525.
20. Rabeharisoa V. From representation to mediation: the shaping of collective mobilization on muscular dystrophy in France. Soc Sci Med 2006;62: 564-576. (Pubitemid 41797014)
21. Boon W, Broekgaarden R. The role of patient advocacy organisations in neuromuscular disease R&D-The case of the Dutch neuromuscular disease association VSN. Neuromuscul Disord 2010;20:148-151.
22. Sharp RR, Landy DC. The financing of clinical genetics research by disease advocacy organizations: A review of funding disclosures in biomedical journals. Am J Med Genet A 2010;152A:3051-3056.
23. Terry SF, Horn EJ, Scott J, Terry PF. Genetic Alliance Registry and BioBank: a novel disease advocacy-driven research solution. Per Med 2011;8: 207-213.
24. Disease InfoSearch. 2007. Genetic Alliance. http://www. geneticalliance. org/diseaseinfosearch. Accessed 22 April 2011.
25. International Association of Patients' Organizations, 2010. International Association of Patients' Organizations Membership Criteria. http://www. patientsorganizations.org/showarticle.pl?id-294;n-9822. Accessed 22 April 2011.
26. Cody JD. Creating partnerships and improving health care: the role of genetic advocacy groups. Genet Med 2006;8:797-799. (Pubitemid 44973769)
27. Seifer SD, Michaels M, Collins S. Applying community-based participatory research principles and approaches in clinical trials: forging a new model for cancer clinical research. Prog Community Health Partnersh 2010;4: 37-46.
28. Kinder BW, Sherman AC, Young LR, et al. Predictors for clinical trial participation in the rare lung disease lymphangioleiomyomatosis. Respir Med 2010;104:578-583.
29. Landy DC, Sharp RR. Examining the potential for exploitation by local intermediaries. Am J Bioeth 2010;10:12-13.
30. Dresser R. When Science Offers Salvation: Patient Advocacy and Research Ethics. Oxford University Press: New York, 2001.
31. Wästfelt M, Fadeel B, Henter JI. A journey of hope: lessons learned from studies on rare diseases and orphan drugs. J Intern Med 2006;260: 1-10. (Pubitemid 43894064)
32. Knight AW, Senior TP. The common problem of rare disease in general practice. Med J Aust 2006;185:82-83. (Pubitemid 44164816)